• NatureSynthetic

Associated products


Our Abpromise guarantee covers the use of ab4985 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

  • Applications


  • FormLiquid
  • Additional notes

    This peptide may be used for neutralization and control experiments with the polyclonal antibody that reacts with this product and Dyn 2, catalog ab3457. Using a solution of peptide of equal volume and concentration to the corresponding antibody will yield a large molar excess of peptide (~ 70-fold) for competitive inhibition of antibody-protein binding reactions.

  • Concentration information loading...

Preparation and Storage

  • Stability and Storage

    Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.

General Info

  • Alternative names
    • CMT2M
    • CMTDI1
    • CMTDIB
    • DI CMTB
    • Dnm2
    • DYN II
    • DYN2
    • DYN2_HUMAN
    • Dynamin II
    • Dynamin-2
    • Dynamin2
    • DynaminII
    • DYNII
    see all
  • FunctionMicrotubule-associated force-producing protein involved in producing microtubule bundles and able to bind and hydrolyze GTP. Most probably involved in vesicular trafficking processes, in particular endocytosis.
  • Tissue specificityUbiquitously expressed.
  • Involvement in diseaseDefects in DNM2 are a cause of centronuclear myopathy autosomal dominant (ADCNM) [MIM:160150]; also known as autosomal dominant myotubular myopathy. Centronuclear myopathies (CNMs) are congenital muscle disorders characterized by progressive muscular weakness and wasting involving mainly limb girdle, trunk, and neck muscles. It may also affect distal muscles. Weakness may be present during childhood or adolescence or may not become evident until the third decade of life. Ptosis is a frequent clinical feature. CNMs comprise a wide spectrum of phenotypes, ranging from severe neonatal to mild late-onset familial forms. The most prominent histopathologic features include high frequency of centrally located nuclei in muscle fibers not secondary to regeneration, radial arrangement of sarcoplasmic strands around the central nuclei, and predominance and hypotrophy of type 1 fibers.
    Defects in DNM2 are the cause of Charcot-Marie-Tooth disease dominant intermediate type B (CMTDIB) [MIM:606482]. Charcot-Marie-Tooth disease (CMT) is a clinically and genetically heterogeneous disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. CMTDIB is a form of Charcot-Marie-Tooth disease characterized by clinical and pathologic features intermediate between demyelinating and axonal peripheral neuropathies, and motor median nerve conduction velocities ranging from 25 to 45 m/sec.
  • Sequence similaritiesBelongs to the dynamin family.
    Contains 1 GED domain.
    Contains 1 PH domain.
  • Cellular localizationCytoplasm. Cytoplasm > cytoskeleton. Cell junction > synapse > postsynaptic cell membrane > postsynaptic density. Cell junction > synapse. Microtubule-associated. Also found in the postsynaptic density of neuronal cells.
  • Information by UniProt

References for Dynamin 2 peptide (ab4985)

ab4985 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab4985.
Please use the links above to contact us or submit feedback about this product.